Gemcitabine as first-line therapy for high-grade non-muscle invasive bladder cancer: results from a tertiary center in the contemporary BCG-shortage era

BACKGROUND: To evaluate the safety profile and efficacy of intravesical gemcitabine as first-line adjuvant therapy for non-muscle invasive bladder cancer (NMIBC) in the setting of ongoing Bacillus Calmette-Guérin (BCG) shortage. METHODS: We performed an institutional, retrospective review of patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Jiping, Funk, Joel, Lee, Benjamin R., Hsu, Chiu-Hsieh, Messing, Edward M., Chipollini, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323448/
https://www.ncbi.nlm.nih.gov/pubmed/37426602
http://dx.doi.org/10.21037/tau-22-772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323448/
https://www.ncbi.nlm.nih.gov/pubmed/37426602
http://dx.doi.org/10.21037/tau-22-772

Ejemplares similares